Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Subcutaneous CUV1647 (Afamelanotide) Implants for Prevention of Pre-Cancerous Skin Lesions in Organ Transplant Recipients
2007-007015-89Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jun 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in actinic keratosis (AK) and cutaneous squamous cell carcinoma (cSCC) comparing CUV1647 implant with Placebo implant (2 arms). Primary endpoints: Change in number of actinic keratoses and Incidence of cutaneous squamous cell carcinoma. Started Jun 2008; status: completed.
02
Drugs
Afamelanotide
03
Conditions
actinic keratosis (AK)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2007-007015-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007015-89.